A global pharmaceutical company headquartered in Japan is looking for partnering and in-licensing opportunities across the globe. The firm is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
The firm is currently looking for innovative therapeutics targeting cardiovascular-metabolic diseases including type 2 diabetes, obesity, and peripheral arterial disease, acute/chronic heart failure, stroke, and kidney disease. In the oncology space, the firm seeks biologics or molecular targets focusing on tumor cell proliferation, resistance to anti-tumor therapies, cancer immunotherapy, cancer stem cell, and cancer metabolism.
The firm also seeks new platform technologies targeting organ fibrosis and NAFLD/NASH, neurology, immunology, rare diseases, mitochondrial disease, and nucleic acid therapeutics. The following areas are currently out of focus: hypertension, thrombosis, dyslipidemia, psychiatric diseases, and immunodeficiency.
The firm partners with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a Reply